- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC February Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Mesalazine has been accepted for mild and moderate exacerbations of ulcerative colitis and for maintenance of remission in ulcerative colitis and Crohn's disease.

Valsartan and losartan 100mg/hydrochlorothiazide 12.5mg have been accepted for the treatment of hypertension, the latter when monotherapy with either agent fails.

Glyceryl trinitrate 0.4% ointment (Rectogesic®) was rejected because the economic case was insufficiently robust to gain acceptance. This was the fourth submission to be rejected.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.